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Objective: Anemia and secondary hyperparathyroidism are the two most common
complications associated with chronic kidney disease. Erythropoiesis-stimulating agents
(ESAs) are widely used in the management of anemia in hemodialysis patients. A reverse
correlation has been established between hyperparathyroidism and hemoglobin levels.
The aim of this retrospective study is to evaluate the relationship of high-dose ESAs and
hyperparathyroidism in hemodialysis patients with anemia.
Methods:A total of 240 uremic patientsmaintained on regular hemodialysis were enrolled
in this study. Among them, 142 patients were treated with Epiao® (epoetin-alfa) and
98 patients were treated with Recormon® (epoetin-beta). The target hemoglobin con-
centration was 110–130 g/L. Laboratory measurements including hemoglobin, calcium,
phosphorus, albumin, intact-parathyroid hormone (iPTH), serum ferritin, and transferrin
saturation were collected.
Results: Hemoglobin concentration increased as iPTH level decreased by stratification.
However, no significant association between anemia and calcium or phosphorus level
was found. Patients with iPTH levels within 150–300pg/mL had the highest levels of
hemoglobin, serum ferritin, and transferrin saturation. Patients treated with Recormon
and Epiao had similar hemoglobin concentrations. However, the dose of Recormon for
anemia treatment was significantly less than that the dose of Epiao (P<0.05). The level
of iPTH in the Recormon group was significantly lower than in the Epiao group. In patients
with hemoglobin levels between 110 and 130g/L (P<0.05), iPTH level was found to be
significantly lower in patients treated with lower doses of ESAs than in patients treated with
higher doses of ESAs, no matter which ESA was used (Recormon or Epiao, P<0.05).
Conclusion: The dose of ESAsmight be positively associated with iPTH level, suggesting
that a reasonable hemoglobin target can be achieved by using the lowest possible ESA
dose.
Keywords: erythropoiesis-stimulating agent, chronic kidney disease, hemodialysis, hemoglobin, parathyroid
hormone
Abbreviations: BUN, blood urea nitrogen; CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent;
Hb, hemoglobin; iPTH, intact-parathyroid hormone; Scr, serum creatinine.
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INTRODUCTION
Chronic kidney disease (CKD) is highly prevalent worldwide.
In China, nearly 1 in 10 people have some degree of kidney
dysfunction, totaling to almost 150 million patients (1). Anemia
and secondary hyperparathyroidism are the two most common
complications associated with CKD (2, 3). In fact, it has been
reported that nearly 90% of patients with advanced CKD (clas-
sified as stage 4 and 5 CKD) suffer from anemia (4). The onset
and severity of anemia has been shown to be well correlated with
the decline in glomerular filtration rate (4). Early identification,
evaluation, and treatment of anemia may decrease morbidity
and mortality, as well as improve the quality of life, in CKD
patients.
Secondary hyperparathyroidism is characterized by elevated
serum parathyroid hormone (PTH) levels. Excess PTH may
impair erythropoiesis by exerting a direct toxic effect on erythroid
progenitor cells and an indirect effect through bone marrow
fibrosis induction (5, 6). In addition, low hemoglobin concen-
tration in uremic patients may have resulted from an increase
in erythrocyte osmotic fragility due to high PTH concentra-
tion (7). A reverse correlation has been established between
PTH and hemoglobin levels (8–10). Meytes et al. found that
PTH concentrations within 7.5–30U/mL, which is comparable
to serum PTH levels in uremic patients, induced the significant
inhibition of burst forming unit-erythroid (BFU-E) growth in
murine bone marrow cultures, suggesting a possible pathway for
the involvement of excess PTH in the genesis of the anemia of
uremia (11).
Erythropoiesis-stimulating agents (ESAs) have become a hall-
mark of anemia therapy in patients with CKD and are the most
commonly prescribed medication in dialysis patients, with >95%
utilization in China (1). The first recombinant human erythropoi-
etin, epoetin-alfa, was licensed in the United States in 1988 (12).
Epoetin-alfa and Epoetin-beta are short-acting and cost-effective
therapeutic agents and are administered — one to three times
weekly in majority of CKD patients. However, its dosage increases
with an extended dosing interval to achieve or maintain a target
hemoglobin level. Epiao® (3,000μ/tube) is a kind of Epoetin-alfa
widely used in China, while Recormon® (2,000μ/tube) is a kind of
Epoetin-beta more commonly used in Europe, and has been used
in China for approximately 4 years.
Findings from recent clinical trials have shown that doses that
achieve high hemoglobin targets raised concerns of an increased
risk of death or adverse outcomes such as thromboembolic events
and stroke (13–16). Andrews et al. found that an increased dose
frequency at a high-dose level increased the incidence of throm-
botic toxicities compared to animals dosed less frequently in lower
dose groups, despite a similarly high hematocrit across all groups
(17), suggesting that a high hematocrit is not the sole causal factor
leading to ESA-related toxicities, but it is also associated with dose
level, dose frequency, and dosing duration. Thus, ESA-related
toxicities independent of high hematocrit should be given close
attention.
At present, limited data are available regarding the possible
relationship between the dose of ESAs and PTH in uremic patients
maintained on regular hemodialysis. This retrospective study
aimed to investigate the association between the dose of ESAs
and intact-PTH (iPTH) levels in hemodialysis patients based on
clinical data in our hospital computer database system.
MATERIALS AND METHODS
Patients and Procedures
This retrospective cohort study was conducted from February
2015 to May 2015 in Xiamen Zhongshan Hospital, Xiamen Uni-
versity, China. This study included uremic patients onmaintained
hemodialysis for at least 3months, who used ESAs for the treat-
ment of anemia. Patients who met the following criteria were
excluded from the study: (1) age<18 years; (2) patients with active
infection, malignancy, iron deficiency anemia (defined as ferritin
<100 ng/mL and saturation <20%), or active bleeding within
3months; (3) patients with incomplete data. Eligible patients were
categorized into two groups, based on the ESA used: Recormon
group and Epiao group.
Data Collection
Data were obtained from Jinshida, the computer database system
of Xiamen Zhongshan Hospital, which recoded the clinical data
of 376 hemodialysis patients. The following data were collected:
age, gender, dry weight, diagnosis of primary diseases, blood urea
nitrogen (BUN), serum creatinine (Scr), hemoglobin, calcium,
phosphorus, albumin, iPTH, serum ferritin, transferrin satura-
tion, and dosage of ESAs. These data were measured in the morn-
ing on the day of hemodialysis (before dialysis). In accordance
with Kidney Disease Improving Global Outcomes (KDIGO)
guidelines, normal hemoglobin level was defined as levels between
110 and 130 g/L in uremic patients with maintained hemodialysis
(8). Reference values for serum calcium and phosphorus were
defined as values within 2.1–2.54 and 1.1–1.78mmol/L, respec-
tively (18). Patients were further classified based on iPTH levels:
150, 300, 600, and 1,500 pg/mL (19, 20).
Study Ethics
This study was carried out by analyzing the retrospective data
obtained from the Electronic Patient Record System of our hos-
pital. The study protocol on human research was approved by
the Ethics Committee of Zhongshan Hospital, Xiamen University.
Written informed consent was obtained from all subjects.
Statistical Analysis
Statistical analysis was performed using SPSS for Windows
software version 17.0. Data were expressed as percentages or
mean Standard Error of Mean (SEM). Demographic data and
laboratory measurements among groups were compared by Pear-
son’s chi-squared test, Fisher’s exact-test, or Yate’s correction for
continuity. A P value <0.05 was considered statistically signifi-
cant.
RESULTS
Characteristics of Uremic Patients
Maintained on Regular Hemodialysis
A total of 240 uremic patients maintained on regular hemodial-
ysis were included in this study. Baseline characteristics of
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TABLE 1 | Baseline characteristics of patients.
Variable All subjects (N=240) ESAs treatment P value
Epiao® (n=142) Recormon® (n=98)
Age, years 57:85 0:78 57:62 0:94 58:47 1:40 0:61
Gender, female, n (%) 92 (38.3) 57 (40.1) 35 (35.7) 0:08
Primary diseases, n (%) 0:99
Glomerular disease 90 (37.5) 52 (36.6) 38 (38.8)
Diabetes mellitus 64 (26.7) 38 (26.8) 26 (26.5)
Hypertension 36 (15.0) 21 (14.8) 15 (15.3)
Lupus nephritis 10 (4.2) 6 (4.2) 4 (4.1)
Autosomal dominant polycystic kidney disease 9 (3.7) 5 (3.5) 4 (4.1)
Gouty nephropathy 8 (3.3) 5 (3.5) 3 (3.1)
Vasculitis with renal damage 5 (2.0) 3 (2.1) 2 (2.0)
Obstructive nephropathy 4 (1.7) 3 (2.1) 1 (1.0)
Chronic transplant nephropathy 4 (1.7) 3 (2.1) 1 (1.0)
Malignant tumor-associated renal injury 3 (1.3) 2 (1.4) 1 (1.0)
Abercrombie degeneration 2 (0.8) 1 (0.7) 1 (1.0)
Unknown reasons 5 (2.1) 3 (2.1) 2 (2.0)
BUN (mmol/L) 23:97 0:44 23:9 0:56 24:08 0:69 0:84
Scr (μmol/L) 990:34 21:02 997:42 26:68 980:08 34:12 0:69
iPTH (pg/mL) 451:65 26:94 531:05 39:57 336:66 57:76 <0:001
Calcium (mmol/L) 2:28 0:01 2:29 0:01 2:27 0:47 0:47
Phosphorus (mmol/L) 2:01 0:04 2:06 0:04 1:94 0:10 0:13
Albumin (g/L) 40:05 0:27 40:2 0:35 39:5 0:44 0:51
Ferritin (ng/mL) 321:21 14:62 298:84 15:72 353:62 27:4 0:08
Transferrin saturation (%) 31:74 0:85 30:61 1:12 33:38 1:28 0:11
Hemoglobin (g/L) 103:15 1:07 102:59 1:38 103:54 1:72 0:53
Dry weight (kg) 59:94 0:60 59:05 0:81 61:22 0:86 0:07
ESAs total dose (μ/week) 5; 781:25 219:59 7; 083:33 264:93 3; 853:66 225:13 <0:001
ESAs dose (μ/kg) 100:25 4:15 124:41 5:67 65:25 3:82 <0:001
ESAs price/week (US$) 24:75 1:34 12:99 0:54 41:79 2:26 <0:001
Categorical variables are presented as percentages; continuous variables are presented as meanSEM. Demographic data and laboratory measurements among groups were
compared by Pearson’s chi-squared test, Fisher’s exact-test, or Yate’s correction for continuity. The price of Epiao® (epoetin-alfa): US$5.5/3,000μ; the price of Recormon®
(epoetin-beta): US$21.5/2,000μ.
patients are shown in Table 1. There were no significant differ-
ences in age, gender, dry weight, primary diseases, BUN, Scr,
hemoglobin, serum phosphate, calcium, albumin, serum ferritin,
and transferrin saturation between the Recormon and Epiao
groups (Table 1, P> 0.05).
The average hemoglobin level of all subjects was
103.15 1.07 g/L. Patients with a hemoglobin levels between 110
and 130 g/L accounted for 30.4% (n= 84). Anemia was divided
into five classes based on hemoglobin level, according to the
severity of anemia (21, 22): hemoglobin level <60 g/L (2.1%,
n= 5), hemoglobin level 60 and <90 g/L (21.7%, n= 52),
hemoglobin level90 and<110 g/L (38.7%, n= 93), hemoglobin
level 110 and <130 g/L (30.4%, n= 73), and hemoglobin level
130 g/L (7.1%, n= 17).
Relationship between the Degree of
Anemia and iPTH
The relationship between different degrees of anemia and iPTH
was analyzed. Results revealed that hemoglobin level was nega-
tively associated with iPTH (Figure 1A; Table 2; P< 0.05). How-
ever, no significant association between anemia and serum cal-
cium or phosphorus level was found (Figure 1B; Table 2; P> 0.05
for both).
Patients with 150–300pg/mL of iPTH Had
the Highest Levels of Hemoglobin, Serum
Ferritin, and Transferrin Saturation
When iPTH level was within 150–300 pg/mL, hemodialysis
patients had the highest average levels of hemoglobin, serum
ferritin, and transferrin saturation; which were 106.25 g/L,
248.98μg/L, and 30.97%, respectively (Figure 2).
Comparison of Recormon vs. Epiao in the
Treatment of Anemia
Patients treated with Recormon and Epiao had similar
hemoglobin levels (103.54 1.72 g/L, n= 98 vs.
102.59 1.38 g/L, n= 142, P> 0.05; Figure 3A). However,
the dosage of Recormon (3,853.66 225.13μ/week, n= 98)
for anemia treatment was significantly less than Epiao
(7,083.33 264.93μ/week, n= 142, P< 0.05; Figure 3B,
Table 1).
Calcium, phosphorus, and albumin serum levels were not
significantly different between the Recormon and Epiao groups
(respectively, 2.27 0.47 vs. 2.29 0.01mmol/L, P> 0.05;
1.94 0.10 vs. 2.06 0.04mmol/L, P> 0.05; 39.5 0.44 vs.
40.2 0.35 g/L, P> 0.05; Figures 3C–E; Table 1).
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The Relationship Between the Doses of
ESAs and iPTH Levels
For all hemodialysis patients, iPTH levels in the Recormon
group was lower than the Epiao group (336.66 57.76 pg/mL,
n= 98 vs. 531.05 39.57 pg/mL, n= 142; P< 0.05; Figure 4A;
Table 1). A similar trend was found in hemodialysis patients with
hemoglobin levels between 110 and 130 g/L (319.50 74.9 pg/mL
in the Recormon group, n= 28 vs. 499.5 64.38 pg/mL in the
Epiao group, n= 45; P< 0.05; Figure 4A).
Among patients with hemoglobin levels between 110
and 130 g/L, iPTH level was 201.54 42.67 pg/mL (n= 10)
in patients treated with Recormon at 2,000μ/week, which
FIGURE 1 | The relationship between hemoglobin concentrations and
iPTH, serum calcium or phosphorus levels. (A) Hemoglobin
concentration increased as iPTH level decreased by stratification. (B) No
significant association between hemoglobin concentration and serum calcium
or phosphorus level was found. Data were calculated by t-test. *P<0.05.
TABLE 2 |Measurements of serum calcium, phosphorus and iPTH levels based on hemoglobin values by stratification.
Hb (g/L) <60 (n=5) 60–90 (n=52) 90–110 (n=93) 110–130 (n=73) >130 (n=17) P value
Ca (mmol/L) – 2.230.03 2.280.02 2.340.02 2.320.04
P (mmol/L) – 2.060.09 2.110.06 2.040.07 2.030.12
iPTH (pg/mL) – 596.4186.17 506.8149.79 435.6269.56* 388.5983.59
No statistically significant differences were found among the groups, except *P=0.042 vs. patients with Hb within 90–110 g/L.
was significantly lower than patients treated with Recormon
at 4,000μ/week (348.16 117.9 pg/mL, n= 13; P< 0.05,
Figure 4B). Similarly, average iPTH level in patients treated
with Epiao at 3,000μ/week was significantly lower than patients
treated with Epiao >6,000μ/week (347.15 75.94 pg/mL, n= 12
vs. 661.01 198.45 pg/mL, n= 27; P< 0.05, Figure 4C).
DISCUSSION
This retrospective study is the first to provide evidence that
higher doses of ESAs (Epoetin-alfa and -beta) might be associ-
ated with higher levels of iPTH in uremic patients maintained
on regular hemodialysis. Furthermore, we found that patients
with iPTH levels within 150–300 pg/mL had the highest levels of
hemoglobin, serum ferritin, and transferrin saturation, which was
consistent with the recommended level of iPTH based on KDIGO
guidelines (9).
Anemia is one of the most common complications of CKD.
The World Health Organization has defined anemia as having a
hemoglobin concentration lower than 13.0 g/dl in men and post-
menopausal women, or a hemoglobin concentration <12.0 g/dL
in other women. The use of ESAs markedly improved the lives
of many anemic patients with CKD. However, high doses of
ESAs have been shown to be associated with increased risk of
adverse outcomes in adults and children with CKD. Patients
FIGURE 2 | Patients with iPTH levels within 150–300pg/mL had the
highest levels of hemoglobin, serum ferritin, and transferrin
saturation. Data are expressed as percentages or meanSEM.
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FIGURE 3 | Comparison of Recormon vs. Epiao in the treatment of anemia. (A) Patients treated with Recormon and Epiao had similar hemoglobin levels
(103.541.72 g/L, n= 98 vs. 102.591.38 g/L, n= 142, P>0.05). (B) The dosage of Recormon for anemia treatment was significantly less than Epiao,
3,853.66225.13μ/week, n= 98 vs. 7,083.33264.93μ/week, n= 142. (C–E) There were no significant differences in calcium (C), phosphorus (D), and albumin
(E) levels between the Recormon and Epiao groups. Data were calculated by t-test; P>0.05.
FIGURE 4 | The association between the dose of ESAs and iPTH levels. (A) The level of iPTH in the Recormon and Epiao groups. (B) In the Recormon group,
iPTH levels in patients treated with Recormon at 2,000 vs. 4,000μ/week. (C) In the Epiao group, iPTH levels in patients treated with Epiao at 3,000 and
>6,000μ/week. Data were calculated by t-test; *P<0.05.
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treated with high ESA doses have a 1.2–1.5 increased risk of
mortality (23). In this study, we found a significant reverse asso-
ciation between iPTH levels and hemoglobin concentrations in
hemodialysis patients treated with ESAs, which is consistent with
findings from previous studies (8–10).
In this study, patients in the Recormon and Epiao groups pre-
sented similar hemoglobin concentrations; however, the dosage
used for Recormon was significantly lower than Epiao. We also
found that iPTH level in the Recormon group was significantly
lower than in the Epiao group. To further determine the asso-
ciation between the dose of ESAs and iPTH levels, we analyzed
the clinical data of patients treated with Recormon or Epiao
separately. The iPTH level was remarkably lower in patients
treated with Recormon at 2,000μ/week than patients treated with
Recormon at 4,000μ/week. A similar trend was found in patients
treated with Epiao at a dosage of 3,000 or 6,000μ/week, suggesting
that high doses of ESAs may be related to high iPTH levels.
These findings indicate that ESA toxicities could not be solely
explained by high hematocrit. Given that high doses of ESAs
may be associated to high levels of iPTH in maintained dialysis
patients, patients with end-stage renal disease may best be man-
aged by minimizing or withholding the dose of ESAs, especially
in patients with recent cardiovascular or cerebrovascular events,
hypertensive emergencies, or acute thromboembolic events. In
fact, considering the increased risk for cardiovascular events at
nearly normal hemoglobin concentrations and high doses of ESAs
in CKD, it is not recommended in Taiwan to use disproportion-
ately high dosages of ESAs to achieve a hemoglobin level within
100–110 g/L (24).
Although the pathogenesis of anemia in CKD is multifac-
torial, the lack of erythropoietin is the main cause of ane-
mia in CKD patients (25). Additional factors contributing
to CKD-associated anemia include iron deficiency, anemia of
inflammation, suppression of erythropoiesis, shortening of red
blood cell survival by uremic toxins, and blood loss such as gas-
trointestinal hemorrhage. Since iron deficiency is also a common
causal factor for anemia, intravenous iron supplementation was
encouraged earlier in Taiwan in 1996. Based on the experience of
CKD anemia management in Taiwan, a reasonable hemoglobin
target can be achieved by using the lowest possible ESA dose and
intravenous iron supplementation (24).
Our study has several limitations. First, this observational study
is a single center study. Second, given the potential confound-
ing and selection bias by indication, cautious interpretation of
these data is needed. Indeed, our observation on the association
between iPTH and ESAs require further exploration by longi-
tudinal prospective studies. Third, there is a predominance in
the number of the patients treated with Epiao (142 for Epiao vs.
98 for Rocormon), which is probably due to the relatively cheap
price of Epiao in comparison with Recormon (Table 1). Fourth,
pharmacological interventions such as antihypertensive agents
might have resulted in transient fluctuations or even interference
in iPTH or hemoglobin levels.
In conclusion, this study demonstrates that higher doses of
ESAs might be associated with higher levels of iPTH in uremic
patients maintained on regular hemodialysis. The involvement of
higher doses of ESAs in the pathogenesis of secondary hyper-
parathyroidism remains unclear and may require further inves-
tigation. Our findings suggest that using the lowest possible ESA
dose can minimize potential risks, while achieving a reasonable
hemoglobin target.
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